Global LAG-3 Targeting Therapy Market Outlook Report 2031: Industry Size, Approved Therapy Dosage, Patent, Sales & Clinical Trials Insight
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Global LAG-3 Targeting Therapy Market Size, Approved Therapy Dosage, Patent, Sales & Clinical Trials Insight 2031" has been added to ResearchAndMarkets.com's offering.
The global LAG-3 targeting therapy market is projected to represent an opportunity of more than USD 5 billion by 2031, supported by commercial validation, expanding immuno-oncology research and the development of new combination therapies. A new market intelligence report provides comprehensive analysis of approved LAG-3 therapies, sales performance, pricing, dosage, patents, clinical trials and the competitive landscape from 2022 through 2031.
Report Findings and Highlights
Commercial Development of the LAG-3 Targeting Therapy Market
The anti-LAG-3 therapy market has progressed from an experimental segment into a commercially validated immuno-oncology category. Opdualag has established clinical and commercial validation for LAG-3 as an actionable immune checkpoint beyond PD-1 and CTLA-4, providing an important foundation for future immunotherapy combinations.
Despite the market's relatively early stage, commercial performance has been strong. Global Opdualag sales exceeded USD 1 billion in 2025, driven by adoption in melanoma treatment and growing physician acceptance of dual checkpoint inhibition. The United States remains the leading revenue-generating market due to early adoption and broad utilization of immuno-oncology therapies.
Market concentration remains high, creating substantial opportunities for pharmaceutical companies developing differentiated LAG-3 antibodies, bispecific molecules and multi-checkpoint combinations. Future revenue growth is expected to be supported by additional indications, new treatment settings and potential regulatory approvals for pipeline candidates.
LAG-3 Clinical Trials and Pipeline Analysis
The report evaluates more than 35 LAG-3 targeting therapies across early-, mid- and late-stage clinical development, including registration-stage studies. It examines clinical progress across melanoma, non-small cell lung cancer, gastric cancer, colorectal cancer, head and neck cancer and other solid tumors.
Combination therapy remains the principal strategy in LAG-3 drug development, particularly through the simultaneous inhibition of LAG-3 and PD-1. Fianlimab in combination with cemiplimab is among the late-stage programs being evaluated in melanoma and non-small cell lung cancer. Bispecific drugs designed to target PD-1 and LAG-3 within a single molecule also represent a significant area of clinical research.
Additional development strategies include triple-checkpoint combinations involving LAG-3, PD-1 and CTLA-4, as well as regimens incorporating cancer vaccines, oncolytic viruses and other immuno-oncology agents. These approaches are being investigated for their potential to address treatment resistance and improve outcomes among patients who do not achieve durable responses with existing checkpoint inhibitors.
Companies Driving LAG-3 Research and Development
The competitive landscape includes major pharmaceutical companies and specialized biotechnology organizations. Bristol Myers Squibb, Regeneron and other established immuno-oncology participants are using existing checkpoint inhibitor portfolios to evaluate LAG-3 combinations across multiple cancer indications. Their development priorities include advancing programs beyond Phase II, pursuing label expansions and establishing new first-line treatment options.
Biotechnology companies, including Y-Biologics, Immutep and Fontacea Pharmaceutical, are contributing to early-stage innovation through bispecific and multispecific antibody platforms. Selected programs are investigating LAG-3 in combination with other immune pathways, including TIGIT and TIM-3.
Licensing agreements, research partnerships and clinical collaborations are expected to remain central to market development. Partnerships between biotechnology innovators and large pharmaceutical companies can provide access to development expertise, global clinical trial infrastructure, manufacturing capacity and commercialization resources.
Future Outlook for LAG-3 Targeting Therapies
Growth in the global LAG-3 targeting therapy market is expected to extend beyond melanoma as clinical programs advance in lung, colorectal, gastric, head and neck, and other solid tumors. Positive late-stage data could establish LAG-3 inhibitors as components of broader first-line immunotherapy combinations in selected cancer types.
Biomarker-guided patient selection may become another important market driver. Clinical development programs are increasingly evaluating defined immune profiles to improve response rates, strengthen therapeutic positioning and support reimbursement decisions.
For investors, pharmaceutical companies and biotechnology developers, LAG-3 represents an emerging immunotherapy market with increasing commercial validation and substantial pipeline potential. With approved therapy sales already exceeding USD 1 billion annually in 2025 and more than 35 therapies under clinical investigation, the category is positioned for continued development through 2031.
Key Topics Covered:
1. Research Methodology
2. Introduction to LAG-3 Targeting Therapies
2.1 LAG-3 As Therapeutic Target
2.2 LAG-3 Targeting Therapies - Mechanism Of Action
2.3 LAG-3 Targeting Approaches
3. Combination Strategies For LAG-3 Targeting Therapies
4. Global LAG-3 Targeting Therapy Market Scenario
4.1 Current Market Outlook
4.2 Future Market Outlook
5. LAG-3 Targeting Therapy Market Regional Analysis
5.1 US
5.2 EU
5.3 China
5.4 Australia
5.5 UK
5.6 Japan
5.7 Canada
5.8 South Korea
6. Opdualag (Nivolumab & Relatlimab) - Overview, Pricing, Dosing & Sales Analysis
6.1 Overview & Patent Insight
6.2 Pricing & Dosing
6.3 Sales Insight
7. Global LAG-3 Targeting Therapies Clinical Trials Overview
7.1 by Phase
7.2 by Country
7.3 by Company
7.4 by Indication
7.5 by Priority Status
8. Global LAG-3 Targeting Therapies clinical Trials Insight by Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III
9. Marketed LAG3 Inhibitor Clinical Insight
10. LAG-3 Targeting Therapy - Development Trends by Indication
10.1 Cancer
10.1.1 Hematological Malignancies
10.1.2 Solid Tumors
10.2 Autoimmune & Inflammatory Diseases
10.3 Microbial Infections
11. Global LAG-3 Targeting Therapy Market Dynamics
11.1 Market Drivers
11.2 Market Challenges
12. Competitive Landscape
12.1 ABL Bio
12.2 Agenus
12.3 Akeso Biopharma
12.4 Bristol-Myers Squibb
12.5 EpimAb Biotherapeutics
12.6 Immutep
12.7 Innovent Biologics
12.8 Regeneron
12.9 Shanghai Henlius Biotech
12.10 Y-Biologics
List of Figures
Figure 2-1: LAG-3/MHC Class II Signaling Pathway
Figure 2-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 2-3: LAG-3 Inhibitor - Mechanism Of Action
Figure 2-4: LAG-3 Agonist - Mechanism Of Action
Figure 2-5: LAG-3 Depletion - Mechanism Of Action
Figure 2-6: Bispecific Antibodies - Binding Efficacy
Figure 3 1: Possible LAG-3 Combinations
Figure 4-1: Global - LAG 3 Targeting Therapy Market (US$ Million), 2022-2026
Figure 4-2: Global - LAG 3 Targeting Therapy Market by Region (US$ Million), Q1'2026
Figure 4-3: Global - LAG 3 Targeting Therapy Market by Region (US$ Million), 2025
Figure 4-4: Global - Quarterly LAG 3 Targeting Therapy Market (US$ Million), 2025
Figure 4-5: Global - LAG 3 Targeting Therapy Market by Region (%), 2024
Figure 4-6: Global - LAG 3 Targeting Therapy Market Forecast (US$ Million), 2026-2031
Figure 4-7: Global LAG-3 Targeting Therapy Market - Future Outlook
Figure 5-1: EU - Research Institutes & Hospitals Conducting LAG-3 Therapy Clinical Trials
Figure 6-1: Opdualag - Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year by Region
Figure 6-3: US - Cost Per Unit & Supply Of Opdualag (US$), May'2026
Figure 6-4: UK - Cost Per Unit & Supply Of Opdualag (US$), May'2026
Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2026
Figure 6-6: Global - Opdualag Annual Sales by Region (US$ Million), Q1'2026
Figure 6-7: Global - Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-8: US - Opdualag Annual Sales (US$ Million), 2024-2026
Figure 6-9: US - Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-10: ROW - Opdualag Sales (US$ Million), 2024-2026
Figure 6-11: ROW - Opdualag Quarterly Sales (US$ Million), 2025
Figure 6-12: Opdualag - US v/s ROW Sales (US$ Million), 2024
Figure 6-13: Global - Opdualag Sales (US$ Million), 2024
Figure 6-14: US - Opdualag Sales (US$ Million), 2022-2024
Figure 6-15: US - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 6-16: ROW - Opdualag Sales (US$ Million), 2022-2024
Figure 6-17: ROW - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 7-1: Global - LAG-3 Inhibitor Clinical Trials by Phase (Numbers), 2026-2031
Figure 7-2: Global - LAG-3 Inhibitor Clinical Trials by Country (Numbers), 2026-2031
Figure 7-3: Global - LAG-3 Inhibitor Clinical Trials by Company (Numbers), 2026-2031
Figure 7-4: Global - LAG-3 Inhibitor Clinical Trials by Indication (Numbers), 2026-2031
Figure 7-5: Global - LAG-3 Inhibitor Clinical Trials by Priority Status (Numbers), 2026-2031
Figure 10-1: RELATIVITY-047 Phase 2/3 (NCT03470922) Study - Initiation & Completion Year
Figure 10-2: AK129-102 Phase 1/2 (NCT06642792) Study - Initiation & Completion Year
Figure 10-3: AK129-102 Phase 1/2 (NCT05137054) Study - Initiation & Completion Year
Figure 10-4: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study - Initiation & Completion Year
Figure 10-5: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study - Initiation & Completion Year
Figure 10-6: R2810-ONC-1866 Phase 2 (NCT03916627) Study - Initiation & Completion Year
Figure 10-7: R2810-ONC-2266 Phase 2 (NCT06161441) Study - Initiation & Completion Year
Figure 10-8: J23155 Phase 2 (NCT06205836) Study - Initiation & Completion Year
Figure 10-9: RELATIVITY-104 Phase 2 (NCT04623775) Study - Initiation & Completion Year
Figure 10-10: RELATIVITY-1093 Phase 3 (NCT06561386) Study - Initiation & Completion Year
Figure 10-11: J1714 Phase 1b (NCT03044613) Study - Initiation & Completion Year
Figure 10-12: HCC 18-139 Phase 2 (NCT04080804) Study - Initiation & Completion Year
Figure 10-13: CA209-1451 Phase 2 (NCT06624475) Study - Initiation & Completion Year
Figure 10-14: MIA2023/490 Phase 2 (NCT06288191) Study - Initiation & Completion Year
Figure 10-15: MIA2023/489 Phase 2 (NCT06151236) Study - Initiation & Completion Year
Figure 10-16: IMP761-P001 Phase 1 (NCT06637865) Study - Initiation & Completion Year
Figure 11-1: Global LAG-3 Targeting Therapy Market - Drivers & Opportunities
Figure 11-2: Global LAG-3 Targeting Therapy Market - Challenges & Restraints
List of Tables
Table 3-1: Ongoing Preclinical & Clinical Trials For Combination of LAG-3 inhibitors
Table 5-1: Immutep - Active Patents by Region
Table 6-1: Opdualag - Maximum Infusion Volumes & Concentration Ranges by Patient Group
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/jz5yex
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.